HK1030338A1 - Treatment of schizophrenia with ampakines and neuroleptics - Google Patents

Treatment of schizophrenia with ampakines and neuroleptics

Info

Publication number
HK1030338A1
HK1030338A1 HK01101109A HK01101109A HK1030338A1 HK 1030338 A1 HK1030338 A1 HK 1030338A1 HK 01101109 A HK01101109 A HK 01101109A HK 01101109 A HK01101109 A HK 01101109A HK 1030338 A1 HK1030338 A1 HK 1030338A1
Authority
HK
Hong Kong
Prior art keywords
schizophrenia
treatment
ampakines
neuroleptics
relates
Prior art date
Application number
HK01101109A
Other languages
English (en)
Inventor
Steven A Johnson
Gary A Gers
Gary S Lynch
Original Assignee
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1030338(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cortex Pharma Inc filed Critical Cortex Pharma Inc
Publication of HK1030338A1 publication Critical patent/HK1030338A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK01101109A 1997-10-27 2001-02-15 Treatment of schizophrenia with ampakines and neuroleptics HK1030338A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6362797P 1997-10-27 1997-10-27
PCT/US1998/022707 WO1999021422A1 (en) 1997-10-27 1998-10-26 Treatment of schizophrenia with ampakines and neuroleptics

Publications (1)

Publication Number Publication Date
HK1030338A1 true HK1030338A1 (en) 2001-05-04

Family

ID=22050462

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01101109A HK1030338A1 (en) 1997-10-27 2001-02-15 Treatment of schizophrenia with ampakines and neuroleptics

Country Status (15)

Country Link
US (1) US6166008A (es)
EP (1) EP1026950B1 (es)
JP (1) JP2001520978A (es)
CN (1) CN1281335A (es)
AT (1) ATE317226T1 (es)
AU (1) AU745641B2 (es)
BR (1) BR9814106A (es)
CA (1) CA2306817A1 (es)
CY (1) CY1105557T1 (es)
DE (1) DE69833451T2 (es)
DK (1) DK1026950T3 (es)
ES (1) ES2258825T3 (es)
HK (1) HK1030338A1 (es)
PT (1) PT1026950E (es)
WO (1) WO1999021422A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1156043E (pt) 1992-07-24 2004-03-31 Univ California Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040229898A1 (en) * 2001-05-25 2004-11-18 The Regents Of The University Of California Cyclic bis-compounds clearing malformed proteins
WO2003014321A2 (en) * 2001-08-10 2003-02-20 The Rockefeller University Compositions and methods for modulation of darpp-32 phosphorylation
NZ540468A (en) * 2003-01-13 2008-03-28 Univ California Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
CA2536975A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
ATE556710T1 (de) * 2004-01-26 2012-05-15 Cortex Pharma Inc Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren
US8415298B2 (en) 2004-06-21 2013-04-09 The Board Of Trustees Of The Leland Stanford Junior University Of Stanford Administration of FGF2 for treamtent of anxiety
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
CN101065014A (zh) * 2004-09-23 2007-10-31 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2006091716A2 (en) * 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
EP1877379B1 (en) 2005-04-13 2013-01-16 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
EP1951908B1 (en) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
WO2007060144A2 (en) * 2005-11-22 2007-05-31 Neurosearch A/S Novel quinoxaline derivatives and their medical use
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
WO2008036282A1 (en) * 2006-09-18 2008-03-27 The Regents Of The University Of Californina Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073804B1 (en) 2006-10-12 2017-09-13 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044027A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical compounds having hsp90 inhibitory or modulating activity
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
CA2695742C (en) 2007-08-10 2012-11-27 Rudolf Mueller Bicyclic amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
EP2391621A4 (en) * 2009-02-02 2012-07-25 Cortex Pharma Inc BICYCLIC AMIDE DERIVATIVES FOR ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
EP2801377B1 (en) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
WO2013184824A1 (en) 2012-06-05 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
RS65621B1 (sr) 2018-04-18 2024-07-31 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, sastavi i njihova upotreba
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) * 1995-04-07 1995-05-31 Inst Of Psychiatry Novel method
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
PT1026950E (pt) 2006-06-30
ATE317226T1 (de) 2006-02-15
BR9814106A (pt) 2000-10-03
WO1999021422A1 (en) 1999-05-06
EP1026950A1 (en) 2000-08-16
DK1026950T3 (da) 2006-06-26
CY1105557T1 (el) 2010-07-28
CN1281335A (zh) 2001-01-24
JP2001520978A (ja) 2001-11-06
US6166008A (en) 2000-12-26
AU745641B2 (en) 2002-03-28
DE69833451T2 (de) 2006-09-28
ES2258825T3 (es) 2006-09-01
EP1026950A4 (en) 2004-07-07
DE69833451D1 (de) 2006-04-20
AU1365899A (en) 1999-05-17
CA2306817A1 (en) 1999-05-06
EP1026950B1 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
HK1030338A1 (en) Treatment of schizophrenia with ampakines and neuroleptics
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
DE60024588D1 (de) Substituierte porphyrine und deren therapeutische verwendungen
BG100830A (en) Naphthylamides as central nervous system agents
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
PT1446387E (pt) Derivados de aril-1,4-pirazina substituídos
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
DE69813898D1 (de) Substituierte porphyrinen
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
GB0216865D0 (en) Targetted agents for nerve regeneration
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
TW200503717A (en) Substituted 1,4-pyrazine derivatives
WO2001007431A3 (en) Benzothiophene derivatives
DE60029119D1 (de) Disulfidkonjugierte zellgifte und verfahren zur ihrer herstellung und verwendung
TR200000916T2 (tr) İkameli piperidin türevleri.
CA2180155A1 (en) Naphthylamides as central nervous system agents

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF : [73] CORTEX PHARMACEUTICALS, INC - 15241 BARRANCA PARKWAY - IRVINE, CA 92718 - UNITED STATES/UNITED STATES OF AMERICA - THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - 12TH FLOOR, 1111 FRANKLIN STREET - OAKLAND - CALIFORNIA 94607-5200 - UNITED STATES/UNITED STATES OF AMERICA - DATED 15.9.2006

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131026